{"title":"Serum vitamin B12 levels and glycemic fluctuation in patients with type 2 diabetes mellitus.","authors":"Wei Li, Jing Zhao, Ling-Ling Zhu, You-Fan Peng","doi":"10.1177/20420188221102800","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the study was to explore the correlation between serum vitamin B12 levels and glycemic fluctuation in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This study included 202 T2DM patients in whom blood glucose levels were recorded using a continuous glucose monitoring system retrospectively. Glycemic fluctuation was determined using the average daily risk range (ADRR), a diabetes-specific measure of the risk for hyper- and hypoglycemia.</p><p><strong>Results: </strong>Serum vitamin B12 levels were higher in T2DM patients with wider glycemic fluctuations than in those with minor glycemic fluctuations (<i>p</i> < 0.001). We observed a positive correlation between serum vitamin B12 levels and ADRR in both T2DM patients who received and did not receive metformin therapy (<i>r</i> = 0.388, <i>p</i> < 0.001 and <i>r</i> = 0.280, <i>p</i> = 0.004, respectively). Multiple linear regression analysis showed that serum vitamin B12 levels were independently correlated with ADRR in T2DM patients who received and did not receive metformin therapy (beta = 0.367, <i>p</i> < 0.001 and beta = 0.410, <i>p</i> < 0.001, respectively).</p><p><strong>Conclusions: </strong>Serum vitamin B12 levels are correlated with glycemic fluctuation in patients with T2DM and may serve as an underlying useful biomarker of glycemic fluctuation in T2DM patients, treated with or without metformin therapy.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/72/10.1177_20420188221102800.PMC9168854.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188221102800","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 1
Abstract
Purpose: The aim of the study was to explore the correlation between serum vitamin B12 levels and glycemic fluctuation in patients with type 2 diabetes mellitus (T2DM).
Methods: This study included 202 T2DM patients in whom blood glucose levels were recorded using a continuous glucose monitoring system retrospectively. Glycemic fluctuation was determined using the average daily risk range (ADRR), a diabetes-specific measure of the risk for hyper- and hypoglycemia.
Results: Serum vitamin B12 levels were higher in T2DM patients with wider glycemic fluctuations than in those with minor glycemic fluctuations (p < 0.001). We observed a positive correlation between serum vitamin B12 levels and ADRR in both T2DM patients who received and did not receive metformin therapy (r = 0.388, p < 0.001 and r = 0.280, p = 0.004, respectively). Multiple linear regression analysis showed that serum vitamin B12 levels were independently correlated with ADRR in T2DM patients who received and did not receive metformin therapy (beta = 0.367, p < 0.001 and beta = 0.410, p < 0.001, respectively).
Conclusions: Serum vitamin B12 levels are correlated with glycemic fluctuation in patients with T2DM and may serve as an underlying useful biomarker of glycemic fluctuation in T2DM patients, treated with or without metformin therapy.
目的:探讨2型糖尿病(T2DM)患者血清维生素B12水平与血糖波动的相关性。方法:采用回顾性连续血糖监测系统记录202例T2DM患者的血糖水平。血糖波动是通过平均每日风险范围(ADRR)来确定的,这是一种针对糖尿病的高血糖和低血糖风险测量方法。结果:血糖波动较大的T2DM患者血清维生素B12水平高于血糖波动较小的T2DM患者(p r = 0.388, p r = 0.280, p = 0.004)。多元线性回归分析显示,接受或未接受二甲双胍治疗的T2DM患者血清维生素B12水平与ADRR独立相关(β = 0.367, p p)。结论:血清维生素B12水平与T2DM患者血糖波动相关,可作为T2DM患者接受或未接受二甲双胍治疗时血糖波动的潜在有用生物标志物。